Literature DB >> 8730339

Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease.

E Reinhold-Keller1, K De Groot, H Rudert, B Nölle, M Heller, W L Gross.   

Abstract

We prospectively studied trimethoprim/sulfamethoxazole (T/S) in inducing remission in 'initial phase' Wegener's granulomatosis (WG), and in sustaining remission in generalized WG, in 72 patients in various disease stages. Nineteen patients with initial phase WG received T/S (2 x 960 mg/day). Another 24 patients with generalized WG received the same dose of T/S (group A) and were compared with 21 patients receiving no further treatment after standard therapy (group B). Eight patients were given T/S plus low-dose prednisone (group C). Eleven of 19 patients (58%) with initial phase WG achieved complete or partial remission lasting a median 43 months (range 6-88 months). Of the remaining eight (42%), five showed local disease progression, and three developed generalized WG. In group A (T/S alone, generalized WG), 10/24 (42%) suffered a relapse after a median 13 months (range 4-58 months). In group B (generalized WG, no further treatment) 29% of patients relapsed after a median 22.5 months (range 18-26 months). All eight patients treated with T/S plus low-dose prednisone (group C) suffered serious relapse after 2-24 months. T/S induced long-term remission in > 50% of patients with initial phase WG; however, neither T/S alone nor T/S plus low-dose prednisone sustained remission in generalized WG.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730339     DOI: 10.1093/oxfordjournals.qjmed.a030133

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  17 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

3.  [Initial skin manifestations of Wegener's disease].

Authors:  M Klammer; G R Hetzel; G Fürst; H E Gabbert; M Megahed; T Ruzicka; U R Hengge
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

4.  [Wegener's granulomatosis in the head and neck region].

Authors:  S Gottschlich; P Ambrosch; W L Gross; B Hellmich
Journal:  HNO       Date:  2004-10       Impact factor: 1.284

Review 5.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

Review 6.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?

Authors:  Antje Mueller; Konstanze Holl-Ulrich; Wolfgang L Gross
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

Review 8.  [Cyclophosphamide versus bolus in Wegener's granulomatosis and other ANCA-related vasculitides: advantages and disadvantages].

Authors:  E Reinhold-Keller; K Warnatz
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

Review 9.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Treatment of ANCA-associated vasculitis.

Authors:  Ulf Schönermarck; Wolfgang L Gross; Kirsten de Groot
Journal:  Nat Rev Nephrol       Date:  2013-11-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.